marketing-medtech

**Founder:** Marie de Tayrac — Présidente / CEO & Co-founder (PU-PH, head of the medical bioinformatics lab, CHU de Rennes / IGDR)
**Background:** clinician | verified: False — Hospital-academic researcher and medical bioinformatician, not a clinician in the patient-treating sense. Marie de Tayrac holds a PhD in Biology & Medical Science (doctoral work in translational oncogenomics) and is a university-hospital academic in Biochemistry and Molecular Biology (MCU-PH since 2011, now PU-PH) at the Medical School / CHU de Rennes, where she heads the medical bioinformatics laboratory. Her work is in genomics and bioinformatics (cancer, rare disease, NGS/variant analysis) at IGDR (UMR 6290 CNRS, Univ Rennes). She is President / CEO & co-founder of GEENG (GEENG GENETIC GENIUS SAS, SIREN 943966812). The "clinician" label is not supported: she is a PhD scientist/bioinformatician with a hospital-academic (PU-PH) post, not an MD clinician treating patients. Note one caveat: a French PU-PH/MCU-PH title carries hospital duties, but the authoritative CV describes her primary role as researcher/bioinformatician, and her training is a science PhD rather than a medical doctorate.
**Stage / fundraise:** Pre-seed / deeptech spin-off. SAS created 2025-04-29, capital 30 000 EUR, ~1 salarié on file (13+ collaborators claimed on site, mostly scientific/academic). Spin-off of CHU de Rennes / IGDR, maturation-funded by SATT Ouest Valorisation and incubated by Le Poool (French Tech Rennes-St Malo). / No confirmed equity round announced. Strong public-funding momentum: Bpifrance i-PhD laureate, candidate referenced as i-Lab 2025 (Technologies médicales, Bretagne) per data.gouv lauréats dataset, SATT Ouest Valorisation maturation financing, and a Le Poool Experimentation Fund grant for the CHU pilot. A brand-new (created 2025-04) deeptech with these grants is almost certainly raising / will raise pre-seed; treat as a fundraising signal but not a confirmed round.
**Regulatory trigger:** DIAGNOW is explicitly positioned as Software as a Medical Device for dPCR/NGS interpretation. The team is "actively pursuing full IVDR certification" (the site also cites ISO 27001, FDA 21 CFR Part 11, HDS, GDPR). The ongoing 1-year CHU de Rennes / METHYS Dx pilot follows a 3-phase path explicitly targeting IVDR. SaMD on this path means a SOUP register, requirements-to-code-to-test traceability and an IEC 62304 software file are squarely ahead.
**Email:** contact@geeng.fr (unconfirmed; pattern-inferred from the geeng.fr domain — NOT a published address) (confidence low) — No email address is published on geeng.fr or its /contact page (form-only; footer notes contact options "coming soon"). No public address found for Marie de Tayrac either. contact@geeng.fr is an inferred generic guess from the confirmed domain, not observed — verify before use or reach out via the website form / LinkedIn instead.
**LinkedIn:** https://www.linkedin.com/in/marie-de-tayrac-41356012/ (company: https://fr.linkedin.com/company/geeng-genetic-genius) **Website:** https://geeng.fr/
**Score:** 12 -> Tier A
**Hook:** GEENG is ~14 months old, deeptech-grant-backed and running a live 1-year CHU de Rennes / METHYS Dx pilot — but DIAGNOW is SaMD on an IVDR path with no CTO and effectively no product-engineering team behind a clinician-led founding trio. That is exactly OmDev's lane: a senior dev team plus a dedicated CTO at a fixed monthly price ~3x cheaper than hiring that in-house, with the client owning the code — and, critically, a pipeline that produces the SOUP register signed at every build and requirements-to-code-to-test traceability that feeds the IEC 62304/MDR-IVDR file (OmDev builds the evidence; it does not certify). Reference points: CadSmile, SpeechLink.

---

## Founder & background
Marie de Tayrac (Présidente / CEO) is a PU-PH clinician-scientist who heads the medical bioinformatics lab at CHU de Rennes and is affiliated with Univ Rennes / CNRS / IGDR ([cvscience](https://cvscience.aviesan.fr/cv/1863/marie-de-tayrac), [IGDR](https://igdr.univ-rennes1.fr/en/group-members-2)). Co-founders are scientists too: Dr Alexandra Lespagnol (molecular biology) and Florent Denoual, MSc (bioinformatics) ([geeng.fr](https://geeng.fr/)). Background is clinical/academic-research — low on the finance/insurance priority axis, but a textbook "non-technical-for-product-engineering" founder.

## Funding & momentum
SAS created 2025-04-29, 30 000 EUR capital, ~1 salarié on file ([Pappers](https://www.pappers.fr/entreprise/geeng-genetic-genius-943966812)). Deeptech spin-off of CHU de Rennes / IGDR, maturation-funded by SATT Ouest Valorisation and incubated by Le Poool ([Ouest Valorisation](https://www.ouest-valorisation.fr/start-up/nos-start-up/geeng-genetic-genious/)). Bpifrance i-PhD laureate and referenced as i-Lab 2025 (Tech médicales, Bretagne). No confirmed equity round, but a brand-new grant-stacked deeptech is almost certainly raising pre-seed.

## Product & regulatory
DIAGNOW is SaMD: it ingests dPCR/NGS data and applies quality criteria, automated calculations, decision rules and report generation for molecular diagnostics ([geeng.fr](https://geeng.fr/), [Le Poool](https://lepoool.tech/geeng-en-experimentation-avec-methys-dx-au-chu-de-rennes/)). The team is "actively pursuing full IVDR certification" (plus ISO 27001, 21 CFR Part 11, HDS), and the CHU/METHYS Dx pilot runs a 3-phase IVDR-targeted path — meaning a SOUP register, traceability and an IEC 62304 software file are directly ahead.

## Pain & buying signals
No CTO and effectively no product-engineering team behind a clinician/biologist/bioinformatician founding trio ([geeng.fr](https://geeng.fr/), [Pappers](https://www.pappers.fr/entreprise/geeng-genetic-genius-943966812)). A live 1-year CHU pilot ([Le Poool](https://lepoool.tech/geeng-en-experimentation-avec-methys-dx-au-chu-de-rennes/)) forces a research prototype to become validated, traceable, certifiable SaMD on a deadline — a heavy IVDR/IEC 62304 load for a sub-team this small.

**Why OmDev fits:** OmDev drops in a senior dev team + a dedicated CTO at a fixed monthly price ~3x cheaper than building that in-house, client owns the code — and the pipeline yields the SOUP register signed at each build plus requirements-to-code-to-test traceability feeding the IEC 62304 / MDR-IVDR file (OmDev builds the evidence, does not certify). Exactly the gap between a clinician-founded SaMD prototype and an IVDR-ready product. Refs: CadSmile, SpeechLink.

---
**Sources:** https://geeng.fr/ · https://geeng.fr/contact · https://www.pappers.fr/entreprise/geeng-genetic-genius-943966812 · https://www.societe.com/societe/geeng-genetic-genius-943966812.html · https://www.ouest-valorisation.fr/nos-actualites/geeng-genetic-genius-la-start-up-rennaise-revolutionne-la-bioproduction-par-le-design-genetique/ · https://www.ouest-valorisation.fr/start-up/nos-start-up/geeng-genetic-genious/ · https://lepoool.tech/geeng-en-experimentation-avec-methys-dx-au-chu-de-rennes/ · https://cvscience.aviesan.fr/cv/1863/marie-de-tayrac · https://igdr.univ-rennes1.fr/en/group-members-2 · https://www.linkedin.com/in/marie-de-tayrac-41356012/ · https://fr.linkedin.com/company/geeng-genetic-genius